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Abstract
Background: Gene-based virotherapy mediated by oncolytic viruses is currently experiencing a renaissance in cancer
therapy. However, relatively little attention has been given to the potentiality of dual gene virotherapy strategy as a
novel therapeutic approach to mediate triplex anticancer combination effects, particularly if the two suitable genes are
well chosen. Both tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and interleukin-12 (IL-12) have been
emerged as promising pharmacological candidates in cancer therapy; however, the combined efficacy of TRAIL and
IL-12 genes for treatment of human hepatocellular carcinoma (HCC) remains to be determined.
Methods: Herein, we investigated the therapeutic efficacy of concurrent therapy with two armed oncolytic
adenoviruses encoding human TRAIL gene (Ad-ΔB/TRAIL) and IL-12 gene (Ad-ΔB/IL-12), respectively, on preclinical
models of human HCC, and also elucidated the possible underlying mechanisms. The effects of Ad-ΔB/TRAIL+Ad-ΔB/
IL-12 combination therapy were assessed both in vitro on Hep3B and HuH7 human HCC cell lines and in vivo on
HCC-orthotopic model established in the livers of athymic nude mice by intrahepatic implantation of human
Hep3B cells.
Results: Compared to therapy with non-armed control Ad-ΔB, combined therapy with Ad-ΔB/TRAIL+Ad-ΔB/IL-12
elicited profound anti-HCC killing effects on Hep3B and HuH7 cells and on the transplanted Hep3B-orthotopic model.
Efficient viral replication and TRAIL and IL-12 expression were also confirmed in HCC cells and the harvested tumor
tissues treated with this combination therapy. Mechanistically, co-therapy with Ad-ΔB/TRAIL+Ad-ΔB/IL-12 exhibited an
enhanced effect on apoptosis promotion, activation of caspase-3 and-8, generation of anti-tumor immune response
evidenced by upregulation of interferon gamma (IFN-γ) production and infiltration of natural killer-and antigen
presenting cells, and remarkable repression of intratumor vascular endothelial growth factor (VEGF) and cluster of
differentiation 31 (CD31) expression and tumor microvessel density.
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Conclusions: Overall, our data showed a favorable therapeutic effect of Ad-ΔB/TRAIL+Ad-ΔB/IL-12 combination
therapy against human HCC, and may therefore constitute a promising and effective therapeutic strategy for treating
human HCC. However, further studies are warranted for its reliable clinical translation.
Keywords: Dual gene virotherapy, Oncolytic adenoviruses, Interleukin-12, Tumor necrosis factor-related
apoptosis-inducing ligand (TRAIL), Hepatocellular carcinoma
Background
Hepatocellular carcinoma (HCC), the 3rd leading cause
of cancer-related deaths globally [1, 2], is an aggressive
primary liver cancer that its medical therapy represents
an important challenge and area of active investigation
[3]. In this regard, fewer than 25 % of HCC patients are
candidates for curative surgical resection or transplant-
ation, and the earlier therapy with standard chemothera-
peutic drugs such as doxorubicin and cisplatin exhibited
only low objective response rates (typically <10 %) and
accompanied with high toxicity side effects [2, 4]. Fur-
thermore, despite the clinical approval of new drugs with
more specific targets such as sorafenib and bevacizumab
for treatment of advanced HCC, their overall therapeutic
outcome and survival benefit remains poor and haven’t
shown any imposing results, and they are also associated
with significant toxicity [2, 4]. Therefore, there is a para-
mount medical demand to explore new therapeutic
strategies to improve the management of HCC. To that
end, cancer gene therapy coupled with therapeutically
useful oncolytic viruses (OVs), including oncolytic ade-
noviruses (OAds), is being the most attractive thera-
peutic approach in this setting [5–7].
Over the past two decades, gene therapy, mediated by
viral and non-viral vectors, has been developed as a
promising pharmacological approach to provide poten-
tial treatment options for a variety of cancers and other
dark diseases that would otherwise be considered
untreatable by conventional drugs [7]. Furthermore,
utilization of cancer virotherapy by using replication-
competent OAds and other OVs has recently emerged
as a novel therapeutic tool; and this premise lies in their
preferential and selective replication in cancer cells while
sparing normal cells [5–11]. Interestingly, clinical trials
using OAd have achieved an obvious anti-cancer effect
in patients with head and neck cancer [7]; and to date,
hundreds of HCC patients have been treated with this
strategy in phase 1 and II clinical trials with encouraging
emerging data [6]. However, a single treatment modality
may not be sufficient to achieve satisfactory anticancer
effect, because most cancers arise from abnormalities in
multiple genetic and signal transduction pathways and
have complexity and heterogeneity of tumor cells
growth, progression and metastasis [12]. Therefore,
application of combined therapeutic approaches with
different mechanisms to affect multiple tumorigenesis
and cancerous pathways has been suggested as an
important tactic for effective clinical cancer therapy.
Toward this goal, many trials based on arming of OAds
with an immuno-stimulatory-, a pro-apoptotic- or an-
other anti-oncogene or tumor suppressor gene were
conceived in various studies and have shown improved
their antitumor efficacies [5, 7–10]. By far, recent modi-
fication of this strategy to cancer targeting dual gene
virotherapy; in which OAds have been utilized to simul-
taneously express dual anticancer genes, have attracted a
further deal of interest in providing more satisfactory
multimodal cancer killing mechanisms through the se-
lective viral lytic effect on cancer cells and the additive
or synergetic interaction between the two expressed
anti-cancer genes [13–15].
Human HCC has a notorious resistant to apoptosis in-
duced by conventional chemotherapeutic drugs and
thereby development of new modalities to trigger apop-
tosis in HCC may result in new effective therapeutic
tools [12, 16]. In that respect, TRAIL has been proved as
a safe and a promising agent for apoptosis-mediated
therapy, whereby it offers a fulminant apoptotic effect in
various human cancer cell types [17–19], including HCC
[20], while showing only negligible effects on normal
cells including normal liver cells [17–20]. With respect
to the liver, TRAIL has also served as a new therapy for
liver fibrosis/cirrhosis in addition to its unique tumouri-
cidal properties [21]. Despite these advantages, earlier
clinical trials using recombinant TRAIL or soluble
TRAIL receptor-agonists for treatment of cancer
patients have been halted due to very short blood circu-
lation half-life and poor pharmacokinetic property; indi-
cating that TRAIL monotherapy is not sufficient [16, 18,
19, 21]; and suggesting the importance of TRAIL com-
bination therapy with other potential anticancer agents/
modalities to restore TRAIL-apoptotic functionality and
to improve overall tumouricidal response [16]. In sup-
port, OAd-mediated combined gene delivery of TRAIL
with another antitumor gene has resulted in a more po-
tent antitumor effect than OAd-mediated TRAIL gene
delivery alone [13, 14].
In a constant line, cytokine-based cancer immunotherapy
has been pursued in a number of ways and now is becom-
ing a clinical reality. In that respect, IL-12, a Th1-cytokine,
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boosts a potent ability to induce antitumor-specific immun-
ity through pleiotropic effects on natural killer (NK)-and
other different immune cells; suggesting its potentiality in
treating advanced cancer [22–24]. IL-12 has also shown to
have antiangiogenic property and remodeling effect on the
peri-tumor extracellular matrix and tumor stroma [23].
Nevertheless, like TRAIL, the robust antitumor activities
exerted by using human recombinant IL-12 has not yet
been successfully translated and sustained into the clinics
due to its poor pharmacokinetics associated with shorten-
ing antitumor efficacy [23]. The logical consequence of
these setbacks was the commencements of development of
IL-12-based gene therapy to not only optimize IL-12′s in
situ expression in the patients’ tumor tissues but also to
increase its clinical efficacy and minimize its systemic side
effects [24]. For instance, adenovirus-delivered IL-12 gene
in a cancer cell-restricted manner without overlapping
toxicities has been demonstrated in a number of animal
studies; however, the majority of these studies have also
highlighted the importance of its combination with add-
itional anticancer gene or therapeutic modality to further
improve its overall anticancer properties [22–26].
Of note, the differences of their anti-cancer mechanisms
can strongly support the potential benefit of TRAIL and
IL-12-based combination therapy. In agreement, co-
therapy with recombinant TRAIL and IL-12 proteins has
been found to significantly sensitize HCC cells to TRAIL’s
apoptotic effect [27]; and treatment with IL-12 has shown
to upregulate TRAIL expression on NK cells and contrib-
utes to IFN-γ-dependent NK cell protection from tumor
metastasis [28]. Based on these encouraging data, it there-
fore may be hypothesizing that their combined therapy
through the strategy of cancer targeting dual gene virother-
apy may renew interest and represent a meaningful thera-
peutic maneuver in cancer therapy. However, to best of
our knowledge the reliability of such strategy for treatment
of HCC has not been sufficiently investigated far. There-
fore, in the present study we generated two OAds armed
with human TRAIL and IL-12 gene (Ad-ΔB/TRAIL and
Ad-ΔB/IL-12, respectively) and their combination therapy
was assessed both in vitro on human HCC cell lines and in
vivo on an orthotopic human HCC model induced in the
liver lobules of nude mice. Overall, our results showed that
combined therapy with Ad-ΔB/TRAIL plus Ad-ΔB/IL-12
had enhanced anti-HCC effect at the in vitro and in vivo
levels, and was closely associated with enhanced activation
of apoptosis and anti-tumor immunity and repression of
tumor angiogenesis and vascularization.
Methods
Cell lines and culture conditions
The Hep3B human HCC cell line, the WRL68 human
normal liver cell line, and the HEK293 human embryonic
kidney cell line expressing the E1A region of Ad5 were
obtained from the American Type Culture Collection
(ATCC, Manassas, VA, USA), while the HuH7 human
HCC cell line was obtained from Japan Health Science
Research Resources (JCRB Genebank, Osaka, Japan). All
cell lines were cultured in Dulbecco’s modified Eagle’s
medium (DMEM; Thermo Fisher Scientific, Inc., Wal-
tham, MA, USA) supplemented with 10 % fetal bovine
serum (Gibco-BRL, Grand Island, NY, USA), 2 mmol/L
glutamine, 50 units/ml penicillin, and 50 μg/ml strepto-
mycin (Gibco-BRL, Grand Island, NY, USA). All cells
were maintained at 37 °C in a humidified incubator
with 5 % CO2.
Generation and purification of oncolytic adenoviruses
expressing human TRAIL or human IL-12 transgene
A conditionally replication-competent oncolytic adeno-
virus (Ad-ΔB) mutated in E1A and deleted in E1B regions
was generated as previously described [22]. To generate
Ad-ΔB-expressing human TRAIL gene (Ad-ΔB/TRAIL)
or human IL-12 gene (Ad-ΔB/IL-12), a DNA region of
human TRAIL or IL-12 was first amplified by PCR with
the following primer sets: hTRAIL; 5′-ATCGCCCGGAT
TAAGAAA-3′ (sense primer), 5′-CAAGTGCAAGTTG
CTCAGGA-3′ (antisense primer), IL-12; 5′- CCTC
CTTGTGGCTACCCTGG-3′ (hp35 sense primer), 5′-
GAAGCATTCAGATAGCTCATCAC-3′ (hp35 antisense
primer), 5′- AGCAAGATGTGTCACCA-3′ (hp40 sense
primer), 5′-TTAGGTTCTGATCCAGGA-3′ (hp40 anti-
sense primer). Hp35 and hp40 are the light and heavy
chains of human IL-12, respectively. Each amplified PCR
product was then sub-cloned into pSP72 Ad shuttle vector
containing the E3 region of Ad type 5 (pSP72-E3; pro-
mega, Madison, WI) to generate a pSP72-TRAIL and a
pSP72-IL-12 Ad shuttle vector, respectively. The shuttle
vectors were then linearized with restriction enzyme
digestion, co-transformed with Ad-ΔB DNA into Escheri-
chia coli BJ5183, and cultured overnight for homologous
recombination. To verify the respective homologous
recombinants, the plasmid DNA purified from overnight
E. coli culture was digested with HindIII, and the digestion
pattern was confirmed by PCR analysis. The resultant
homologous plasmid DNA recombinants were further
digested with PacI and transfected into HEK293 cells to
generate Ad-ΔB/TRAIL and Ad-ΔB/IL-12. The three gen-
erated OAds (Ad-ΔB, Ad-ΔB/TRAIL, and Ad-ΔB/IL-12)
were further propagated in HEK293 cells, purified by CsCl
gradient density purification method, and then dissolved
in storage buffer (10 mM Tris, 4 % sucrose, 2 mM MgCl2)
and stored at−80 °C until use [29, 30]. The number of viral
particle (Vp) for each virus was calculated from measure-
ments of optical density at 260 nm (OD260), where one ab-
sorbency unit is equivalent to 1.1 × 1012 viral particles per
milliliter (VP/mL) [30]. Infectious titers (plaque-forming
units (PFU) per milliliter) were also determined by
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limiting dilution assay on HEK293 cells; the multiplicity of
infection (MOI) was calculated from the infectious titers.
Validation of TRAIL and IL-12 expression and viral
replication in the transfected HCC cells
HuH7 human HCC cells were plated onto 24-well plates at
a density of 4 × 104 cells per well. After 24 h, the cells were
treated with PBS, Ad-ΔB, or Ad-ΔB/TRAIL+ Ad-ΔB/IL-12
at a MOI of 5 for each virus in serum-free DMEM. After
48 h post-treatment, the cell lysates and conditioned
medium were harvested and used to measure the ex-
pression pattern of TRAIL and IL-12 at their mRNA and
protein levels by using Q-RT-PCR and ELISA assay,
respectively. For Q-RT-PCR, total cellular RNA was
extracted from each sample with TRIzol® reagent (Gibco
BRL, Grand Island, NY) according to the manufacturer s
instructions, and cDNA was prepared from 1 μg total RNA
by random priming using a first-strand cDNA synthesis kit
(Promega Corp., Madison, WI), under the following condi-
tions: 95 °C for 5 min, 37 °C for 2 h, and 75 °C for 15 min.
Q-RT-PCR reaction mixtures were assembled using the
AmpiGene™ qPCR Green Mix Lo-ROX (Enzo Life
Sciences, Switzerland), 10 pmol of primers and 50 ng of
cDNA. The relative mRNA expression levels of TRAIL
and IL-12 were determined with the following primer set:
TRAIL; 5′- ATCGCCCGGATTAAGAAACT-3′ (sense
primer), 5′- CAAGTGCAAGTTGCTCAGGA-3′ (anti-
sense primer); IL-12; 5′- AAG GAG GCG AGG TTC
TAA GC-3′ (hp40 sense primer), 5′- AAGAGCCTCT
GCTGCTTTTG-3′ (hp40 antisense primer). Q-RT-PCR
reactions were performed and analyzed using the ABI 7500
Real-Time PCR system (Applied Biosystems, Foster city,
CA), and 18S ribosomal RNA was used as the endogenous
control.
For ELISA, the samples were lysed in ice-cold RIPA
buffer with a proteinase inhibitor cocktail (Sigma), cen-
trifuged, and the concentrations of TRAIL and IL-12
proteins were individually measured in all supernatants
by using conventional ELISA kits (BD, San Jose, CA)
and following the manufacturers’ instructions.
These lysates of the treated HuH7 cells were also used
for determination of viral production by measuring the
expression of Ad E1A protein (as an indicator of viral
replication) by western blotting using rabbit anti-Ad
E1A primary antibody (Santa Cruz Biotechnology, Santa
Cruz, CA) and as described previously [31].
In vitro cell viability (MTT) assay
MTT [3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium
bromide; Sigma Chemical Co., St. Louis, MO, USA] assay
was used to determine in vitro killing effect of Ad-ΔB/
TRAIL+Ad-ΔB/IL-12 on two human HCC cell lines
(Hep3B and HuH7) and compared with their effect on the
normal human liver cells (WRL68) as previously described
[29]. Briefly, the Hep3B, HuH7 and WRL68 cells were
plated onto 24-well plates at about 60 to 70 % conflu-
ence, and then treated with PBS, Ad-ΔB, or Ad-ΔB/
TRAIL+Ad-ΔB/IL-12 at the indicated MOIs (5 and 10
for Hep3B; 10 and 20 for Huh7; and 20 and 50 MOIs
for WRL68). Cells were incubated at 37 °C for 48 h,
and 200 μl MTT (2 mg/ml in PBS) was added to each
well. After incubation for four hours at 37 °C with 5 %
CO2, the supernatant and culture medium was aspi-
rated and 150 μl Dimetylsulfoxide (DMSO) per well
was added to dissolve the insoluble formazan crystals
into a colored solution. Thereafter, the average spectro-
photometric readings of the absorbance at 540 nm from
three replicates of each treatment were determined in a
microplate reader (Bio-Rad 680, Hercules, CA). Cell
viability in each well was calculated according the
following formula: cell survival = (absorbance value of
treated cells-blank)/(absorbance value of untreated con-
trol cells), and expressed as the percentage of untreated
control cells [29].
In vitro cytopathic effect assay
To further confirm the cancer cell-cytopathic effects of
the generated OAds, the human Hep3B and WRL68
cells (4 × 104 cells per well) were cultured and grown to
60–70 % confluence in 24-well plates, and then treated
with Ad-ΔB, or Ad-ΔB/TRAIL+ Ad-ΔB/IL-12 at various
MOIs (1, 2, 5, 10, 20 in Hep3B cells; and 5, 10, 20, 50, 100
in WRL68), followed by incubation for 3 days at 37 °C
allowing viral replication and cell-lysis. The media were
replaced with 500 μl crystal violet solutions (0.5 % crystal
violet in 50 % methanol) and 30 min later all wells were
lightly washed with distilled water, naturally dried and
documented as photographs. Each experiment was re-
peated three times, and PBS-treated cell groups were sim-
ultaneously analyzed and used as a negative control.
In vitro analysis of apoptosis by flow cytometry
HuH7 cells (5 × 105 cells per well) were cultured and
treated with PBS, Ad-ΔB, or Ad-ΔB/TRAIL+Ad-ΔB/IL-12
(at MOI of 5) were incubated for 52 h. subsequently, the
cells were washed once with complete medium, re-
suspended in binding buffer and then stained with
Annexin V-fluorescein isothiocyanate (FITC; 0.5 μg/ml;
as early apoptotic marker) and propidium iodide
(0.6 μg/ml; as late apoptotic marker) (BioVision, Inc.,
Milpitas, CA), according to the manufacturer’s instruc-
tions. After 15 min incubation in the dark at room
temperature, stained cells were immediately analyzed
by flow cytometry (BD, San Jose, CA). All samples were
assayed in triplicate, and total apoptotic cell population
was calculated by the percentage of early apoptotic cells
and late apoptotic cells.
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In vivo orthotopic mouse model of human HCC,
treatment and experimental approaches
An orthotopic transplanted model of human HCC was
established in 6- to 7 weeks-old male athymic nude mice
as described previously [32, 33]. The model was induced
by intrahepatic implantation of 2 × 106 human Hep3B/fluc
cells into the left liver lobes of mice, and the animals were
maintained in laminar flow cabinets under pathogen-free
condition, and all experimental protocols and procedures
were in accordance with the EU Directive 2010/63/EU for
animal experiments. Fifteen days post-Hep3B implant-
ation, bioluminescence imaging was taken to confirm
model establishment; in which mice were anesthetized in
a chamber filled with 2 % isofluorane in oxygen and
injected intraperitoneally with 150 mg/Kg D-luciferin
potassium salt (Caliper, Hopkinton, MA), and then
photographic and bioluminescent images were obtained
from the anesthetized mice using IVIS imaging system
(Xenogen, Alameda, CA). In vivo bioluminescence signals
were calculated as the sum of both prone and supine ac-
quisitions for each mouse after background subtraction
total flux (photons/s) from a total body ROI (region of
interest) as described previously [32]. Survival mice that
their imaged signals reached around 2 × 108 p/s were en-
rolled as positive HCC-bearing mice, and were thereafter
randomized into three groups (n = 10/group) and sys-
temically treated with: PBS alone (Group 1), Ad-ΔB
(Group 2), and Ad-ΔB/TRAIL + Ad-ΔB/IL-12 (Group 3).
The dosage regimen of each OAd was 1 × 1010 VP (diluted
in 200 μL PBS) injected intravenously through the caudal
vein and repeated three times every other day [29]. Three
days after administration of the last dose of each treat-
ment strategy, four mice from each group were randomly
selected, euthanized under general anesthesia (sodium
pentobarbital; 120 mg/kg, i.p.), and their blood samples
and tumor tissues were harvested and employed for the
following purposes: (1) validation of intratumor viral repli-
cation (represented by viral E1A protein expression) and
expression of TRAIL and IL-12 transgenes at their mRNA
and protein levels by the same methodology as described
above; (2) histopathological, immunohistochemical
and in situ apoptosis analyses; (3) measuring of intratu-
mor expression patterns of IFN-γ and VEGF, caspase-3
and 8; and (4) measuring of serum levels of hepato-renal
function biomarkers. Of note, the remaining mice (n = 6
per group) were monitored weekly by bioluminescence
imaging to determine the pattern of tumor response to
the subjected treatments until the end of study (day 14
post-the last treatment dose).
Histopathology, immunohistochemistry and TUNEL assay
Specimens of the harvested livers and tumor tissues
were fixed in 4 % formalin followed by embedding in
paraffin. Tissue sections (4 μm) were subjected to
histopathology (H&E staining), immunohistochemical
(IHC) staining and in situ apoptosis detection by TUNEL
assay. For IHC, after dewaxing, antigen retrieval and en-
dogenous peroxidase blocking steps the sections were
subjected to staining procedures with purified monoclonal
anti-mouse CD11b (BD PharMingen, San Jose, CA); anti-
mouse NK1.1 (Biolegend, San Diego, CA); and anti-rabbit
CD31 (Abcam, Cambrige, MA) primary antibodies, re-
spectively. Subsequently, biotinylated goat anti-mouse or
anti-rabbit immunoglobulins as secondary antibodies and
streptavidin peroxidase complex reagent were applied.
The visualization signals were developed with dia-
minobenzidine (DAB) chromogen substrate (DAKO,
Carpinteria, CA and the slides were counterstained
with Meyer’s hematoxylin and dehydrated through a
series of ethanol and xylenes. In addition, intratumor
microvessel density was microscopically counted in
absolute values as previously described [29, 34]. Fi-
nally, for detection of in situ apoptosis in the tumor
tissues, TUNEL (terminal deoxynucleotidyl transferase
(TdT)-mediated dUTP nick-end labeling) assay was
performed according to the manufacturer’s protocol
(Roche Molecular Biochemicals) as described previ-
ously [34].
Western blot assay of caspases-3 and-8 in the tumor
tissues
Protein expression of two common apoptosis-related
molecules, caspase-3 and caspase—8, was determined
in the harvested tumor tissues treated with PBS, with
Ad-ΔB, or Ad-ΔB/TRAIL+ Ad-ΔB/IL-12 by using
western blot analysis to identify a possible underlying
mechanism involved in treatment-mediated apoptosis.
Briefly, each sample was lysed in ice-cold RIPA buffer
with a proteinase inhibitor cocktail, centrifuged in a
high-speed microcentrifuge for ten minutes, and then
the total protein content was determined in the ex-
tract using a BCA protein assay reagent kit (Pierce, Rock-
ford, IL). For each protein sample, 20 μg was separated by
10 % sodium dodecyl sulfate–polyacrylamide gel electro-
phoresis and transferred onto a PVDF membrane
(Millipore). The membranes were blocked in TBST
(50 mM Tris–HCl, pH 7.6, 150 mM NaCl, 0.2 %
Tween 20) containing 3 % BSA for 2 h, and then in-
cubated with rabbit polyclonal IgG primary antibodies
to caspase-3 and caspase-8 (Cell signaling, Danvers,
MA), and β-actin (Santa Cruz Biotechnology, Santa
Cruz, CA), for overnight at 4 °C. Subsequent in-
cubation with goat anti–rabbit IgG- horseradish per-
oxidase (HRP) secondary antibodies was performed
for 45 min at room temperature, followed by 3–5
washes with TBST buffer, and then the blots were
developed with the enhanced chemiluminescence de-
tection reagents.
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ELISA assays of IFN-γ and VEGF in the tumor tissues
Liver tumor tissue specimens of HCC-bearing mice treated
with PBS, Ad-ΔB, or Ad-ΔB/TRAIL +Ad-ΔB/IL-12 were
homogenized in ice-cold RIPA lysis buffer with a protein-
ase inhibitor cocktail (Santa-Cruz Biotechnology Inc,
Burlingame, CA) and analyzed for total protein content
using a BCA protein assay reagent kit (Pierce). Concentra-
tions of IFN-γ and VEGF in the tumor tissue lysates were
quantitatively measured by using commercially available
ELISA kits (R&D systems, Minneapolis, MN, USA) and ac-
cording to manufacturer’s instructions.
In vivo safety study
At 72 h after the last injected dose of each therapeutic
strategy, blood samples were collected and their ob-
tained sera were prepared form their representatives
whole blood samples and biochemically analyzed to
measure the serum levels of liver function parameters
(ALT AST, and bilirubin), and kidney function parame-
ters (BUN and creatinine) according to their standard
protocols. In addition, the harvested liver tissues of the
different animal groups were subjected to H&E staining
and microscopic examination to assess the possible
changes in their liver morphology.
Statistical analysis
Data were expressed as mean ± SEM. Statistical comparison
was analyzed by one-way analysis of variance (ANOVA)
using the Statistical Package for the Social Sciences (SPSS)
program, version 18, followed by Mann–Whitney test to
compare significance between groups. The difference be-
tween data were considered to be statistically significant
when P <0.05; very significant when p <0.01; and very
much significant when p <0.001.
Results
In vitro co-therapy with Ad-ΔB/TRAIL plus Ad-ΔB/IL-12
exhibited efficient viral replication and TRAIL and IL-12
expression in human HCC cells
In the present study, a control non-armed OAd (Ad-ΔB)
and two independent armed OAds expressing human
TRAIL (Ad-ΔB/TRAIL) and human IL-12 (Ad-ΔB/IL-12)
transgene were generated (Fig. 1). OAds replication
efficiency and the expression pattern of TRAIL and IL-12
transgenes were measured in the human HuH7 HCC cells
treated with PBS, Ad-ΔB, or Ad-ΔB/TRAIL+ Ad-ΔB/IL-12
at a MOI of 5 for each Ad. Both mRNA and protein levels
of either TRAIL or IL-12 was significantly detected only in
HuH7 cells co-transfected with Ad-ΔB/TRAIL plus Ad-
ΔB/IL-12 (Fig. 2a-d). Similarly, there was remarkable ex-
pression of viral E1A protein (as an indicator of viral repli-
cation) in HCC cells treated with Ad-ΔB/TRAIL+ Ad-ΔB/
IL-12 combination therapy than those treated with PBS-or
Ad-ΔB (Fig. 2e). This in turn meant that co-treatment with
Ad-ΔB/TRAIL and Ad-ΔB/IL-12 exhibited simultaneous
and efficient expression of both TRAIL and IL-12, and also
didn’t interfere with viral replication, in human HCC cells.
In vitro co-therapy with Ad-ΔB/TRAIL plus Ad-ΔB/IL-12
exhibited profound anti-proliferative and cytopathic
effects on human HCC cells
We next measured the in vitro suppressive effects of
Ad-ΔB and Ad-ΔB/TRAIL+Ad-ΔB/IL-12 on the prolif-
eration and viability of two human HCC cell lines
(Hep3B & HuH7) by using MTT and crystal violet
assays. Results of MTT assay demonstrated that in a
dose-dependent manner the combined treatment with
Ad-ΔB/TRAIL+Ad-ΔB/IL-12 had resulted in potent kill-
ing effects on the tested Hep3B (Fig. 3a) and HuH7
(Fig. 3b) human HCC cell lines than those achieved by
tretament with Ad-ΔB. The same findings were also
confirmed with crystal violet assay (Fig. 3d), whereby co-
treatment with Ad-ΔB/TRAIL and Ad-ΔB/IL-12 elicited
more cytopathic effect on HCC cells than Ad-ΔB. Fur-
thermore, to evaluate their in vitro safety, the normal
human liver cell lines (WRL68) were infected with Ad-
ΔB or Ad-ΔB/TRAIL+Ad-ΔB/IL-12 at doses of 20 and
50 MOIs in MTT assay (Fig. 3c), and from 1 to 100
MOIs in crystal violet assay (Fig. 3d), and the collective re-
sults showed that Ad-ΔB/TRAIL+Ad-ΔB/IL-12 showed
potent cancer cell killing efficacy in HCC cells (Hep3B
and Huh7), which was markedly higher to that of Ad-ΔB.
In contrast, no high significant difference between the
cytopathic effects of Ad-ΔB and Ad-ΔB/TRAIL+Ad-ΔB/
IL-12 on WRL68 cells at their doses used to induce killing
effect on HCC cells. Together, these results indicate that
Fig. 1 Graphical representation of the constructed and generated non-armed control oncolytic adenovirus (Ad-ΔB) and oncolytic adenovirus
armed with human TRAIL gene (Ad-ΔB/TRAIL) or human IL-12 gene (Ad-ΔB/IL-12). TRAIL or IL-12 gene was incorporated in the E3 region of the
viral backbone under the transcriptional control of the human cytomegalovirus (CMV) promoter
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dual treatment with Ad-ΔB/TRAIL plus Ad-ΔB/IL-12 can
induce potent and HCC-selective cancer cell killing effect
with minimal cytotoxicity in normal liver cells.
Potent in vivo anti-tumor effect of Ad-ΔB/TRAIL/Ad-ΔB/IL-12
combination therapy
An in vivo orthotopic mouse model of human HCC was
used to demonstrate the anti-tumor effect of the different
treatments. Two weeks after intrahepatic implantation of
2 × 106 human Hep3B/fluc cells, bioluminescence signal
was done to confirm model establishment. Mice that their
imaged signals reached around 2 × 108 p/s were thereafter
enrolled as positive HCC-bearing mice and then random-
ized into three groups and intravenously treated with:
PBS, Ad-ΔB, and Ad-ΔB/TRAIL+Ad-ΔB/IL-12, respect-
ively, at a dosage schedule of 1 × 1010 VP of each vector/
injection; three times with two days interval. In vivo
tumor bioluminescence imaging were subsequently taken
on days 0, 7, day 14 post-the last injected dose of each
treatment to determine the tumor response for each treat-
ment. As shown in Fig. 4, combined treatment with Ad-
ΔB/TRAIL plus Ad-ΔB/IL-12 showed marked inhibitory
effect on the intrahepatic implanted tumors; and after
14 days, this combination therapy had resulted in 6.5-fold
greater reduction in the tumor bioluminescence imaging
(P <0.001) compared to a therapy with Ad-ΔB (Fig. 4).
Findings of the histopathological (H&E) examination of
the tumor tissues that were collected 3 days after the last
injected dose of each treatment were in full harmony with
in vivo bioluminescence imaging results and revealed the
presence of a large area of proliferating tumor cells with-
out necrotic changes in the tumor tissues of mice treated
with PBS (Fig. 5a). By contrast, large necrotic areas were
remarkably observed in the tumor tissues of mice co-
treated with Ad-ΔB/TRAIL plus Ad-ΔB/IL-12; reflecting
their extensive in vivo tumouricidal effect. However,
Fig. 2 Validation of in vitro oncolytic adenoviral replication efficiency and the expression patterns of the encoded TRAIL and IL-12 transgenes in
human HCC cells. HuH7 cells were cultured and then treated with PBS, Ad-ΔB, or Ad-ΔB/TRAIL+ Ad-ΔB/IL-12 at a MOI of 5 for each virus. Two
days post-treatment, the cell lysates and conditioned media were harvested and relative mRNA and protein levels of TRAIL (a and b), or IL-12
(c and d) were measured by using Q-RT-PCR and ELISA assays, respectively. Data are represented as mean ± SE. In addition, viral production was
determined by measuring the expression of Ad E1A protein (e) by western blot assay using rabbit anti-Ad E1A primary antibody
El-Shemi et al. Journal of Experimental & Clinical Cancer Research  (2016) 35:74 Page 7 of 16
HCC-bearing mice treated with Ad-ΔB showed only a few
necrotic cells in their tumor tissues (Fig. 5a).
Combined therapy with Ad-ΔB/TRAIL and Ad-ΔB/IL-12 is
associated with induction of antitumour immune
response and inhibition of tumour angiogenesis
To understand the possible underlying mechanisms be-
hind the efficient anti-HCC effect of Ad-ΔB/TRAIL+Ad-
ΔB/IL-12 combination therapy, the expression level of
three cellular markers; NK1.1-, CD11b-, CD31- positive
cells, and the change in the intratumor microvascular
density was examined by IHC. Additionally, the expres-
sion levels of IFN-γ and VEGF were also measured in
the tumor tissues by ELISA assay. As demonstrated in
Fig. 5a, cellular markers of antitumor immune cells such
as natural killer cells (NK1.1-positive cells) and antigen
presenting cells (monocyte/macrophages and dendritic
cells; CD11b-positive cells) were abundantly infiltrated
into tumor tissues of mice treated with Ad-ΔB/TRAIL
plus Ad-ΔB/IL-12 compared with therapy with Ad-ΔB
(Fig. 5a). These IHC observations were also associated
with significant upregulation of IFN-γ production (Fig. 5b)
and downregulation of VEGF expression (Fig. 5c) in the
harvested HCC tumor tissues. Constantly, a marked de-
crease in blood vessels expressing CD31-positive cells
(Fig. 5a) and a significant suppression of vascular density
(Fig. 5d) was also observed in the tumor tissues of animals
received Ad-ΔB/TRAIL+Ad-ΔB/IL-12 combination ther-
apy than other treated groups. In short, these findings sug-
gest that concomitant therapy with Ad-ΔB/TRAIL plus
Ad-ΔB/IL-12 was significantly associated with generation
of anti-tumour specific immune response as well as anti-
Fig. 3 In vitro effects of Ad-ΔB and Ad-ΔB/TRAIL+Ad-ΔB/IL-12 on Hep3B and HuH7 human HCC cells and normal human liver (WRL68) cells.
a Quantitative results of MTT assay showing the inhibitor effects on viability of Hep3B cells at 5 and 10 MOI (the multiplicity of infection) per
virus; (b) Quantitative results of MTT assay showing the inhibitor effects on viability of HuH7 cells at 10 and 20 MOI per virus; and (c) Quantitative
results of MTT assay showing the inhibitor effects on viability of WRL68 cells at 50 MOI per virus. Data are represented as mean ± SE. d
Representatives of semi-quantitative assessment of cytotoxic potency by crystal violet cytopathic effect assay on Hep3B cells (left panel), HuH7
cells (middle panel), and WRL68 cells (right panel) at indicated MOIs. Ad-ΔB = non-armed control oncolytic adenovirus; Ad-ΔB/TRAIL+Ad-ΔB/IL-12
(or Ad-ΔB/TRAIL+IL-12) = combined therapy with two oncolytic adenoviruses encoding human TRAIL and IL-12 genes, respectively
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angiogenesis and antitumor vasculature effect than
therapy with Ad-ΔB.
Ad-ΔB/TRAIL and Ad-ΔB/IL-12 exhibited efficient viral
replication and expression of their armed TRAIL and IL-12
transgenes in the tumor tissues
Furthermore, molecular analysis (Fig. 6a-e) showed that
tumor tissues of animals treated with Ad-ΔB/TRAIL
+Ad-ΔB/IL-12 combined therapy elicited profound ele-
vation in the mRNA and protein levels of TRAIL and
IL-12 transgenes (Fig. 6a-d), as well as in the degree of
intratumor viral replication as reflected by the expres-
sion level of E1A protein (Fig. 6e); suggesting that the
strategy of OAd-mediated TRAIL and IL-12 dual gene
transfer exhibited simultaneous and efficient expression
of the encoded transgenes and didn’t interfere with viral
replication in human HCC tumor tissues.
Combined therapy with Ad-ΔB/TRAIL and Ad-ΔB/IL-12
induces apoptosis and caspases-3 and 8 in both HCC cells
and tumors
To further explore the mechanisms that might be in-
volved in the anti-HCC therapeutic effects of the two
tested treatment approaches, we examined the apoptotic
changes both in vitro on HuH7 cells and in vivo on the
tumor tissues that were collected 3 days after the last
treatment dose with either Ad-ΔB or Ad-ΔB/TRAIL +
Ad-ΔB/IL-12 combination therapy. As demonstrated in
Fig. 7a, in vitro co- treatment with Ad-ΔB/TRAIL and
Ad-ΔB/IL-12 had resulted in approximately 69.6 % of
total Huh7 cell apoptosis (41 % early apoptotic cells and
28.6 % late apoptotic cells), compared to approximately
40.5 % of apoptotic Huh7 cells when treated with Ad-ΔB
(31 % early apoptotic cells and 9.5 % late apoptotic cells).
In agreement with these in vitro results, TUNEL assay,
that was applied to detect in situ apoptotic cells in the
Fig. 4 In vivo antitumor effects of Ad-ΔB and Ad-ΔB/TRAIL+Ad-ΔB/IL-12 on an orthotopic transplanted mouse model of human HCC. The model was
induced by intrahepatic implantation of 2 × 106 human Hep3B/fluc cells into the left liver lobes of mice in athymic nude mice. Positive HCC-bearing
mice were thereafter randomized into three groups (n = 10/group) and through their tail veins they were treated with: PBS alone (Group 1), Ad-ΔB
(Group 2), and Ad-ΔB/TRAIL+Ad-ΔB/IL-12 (Group 3) at a dosage regimen of 1 × 1010 VP in 200 μL PBS of each virus; repeated three times every other
day. Next, the mice were monitored and photographed (a) weekly by in vivo bioluminescence imaging to determine the pattern of tumor response
to the subjected treatments (b) until the end of study (day 14 post-the last treatment dose)
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tumor tissues, revealed that the combination of Ad-ΔB/
TRAIL plus Ad-ΔB/IL-12 had resulted in a more signifi-
cant induction of intratumor apoptosis compared to
therapy with Ad-ΔB (Fig. 5a). This meant that oncolytic
Ad with TRAIL and IL-12 genes were interacted to-
gether to eradicate human HCC cells and tumors by, at
least in part, induction of apoptosis phenomenon. Next,
we proceeded to address the possible underlying mo-
lecular mechanism that could be involved in apoptosis
promotion. Towards this goal, the activity caspase-3 and
caspase-8, well-known apoptosis-inducing molecules,
were measured in the harvested tumor tissues by west-
ern blotting analysis. Our findings demonstrate that
tumors treated with a combination of Ad-ΔB/TRAIL
and Ad-ΔB/IL-12 had significant elevations in cleaved
caspase-3 and caspase-8, than those treated with the
non-armed control Ad-ΔB (Fig. 7b). These results may
therefore imply that the observed apoptotic effect was,
partly, mediated by activating caspase cascade in HCC
cells and tumour tissues.
Biochemical and histological findings of in vivo safety
study
At 72 h after the last injected dose of each treatment,
the serum levels of liver and kidney function parameters
were assessed. Interestingly, as shown in Table 1, there
were no significant differences between the hepato-renal
effects of the administered PBS, Ad-ΔB, nor Ad-ΔB/
TRAIL+Ad-ΔB/IL-12; with one interest exception that
therapy with Ad-ΔB/TRAIL+Ad-ΔB/IL-12 showed more
Fig. 5 Histopathological, immunohistochemical and apoptosis assessments of the harvested tumor tissues from different animal groups. Three
days post-treatment of HCC-bearing mice with PBS, Ad-ΔB, or Ad-ΔB/TRAIL+Ad-ΔB/IL-12 (at a dosage regimen of 1 × 1010 VP in 200 μL PBS of
each virus; repeated three times every other day), the mice were euthanized under general anesthesia and their liver tumor tissues were harvested
and prepared for histopathological, immunohistochemical (IHC) and apoptosis assessments, and measurement of intra-tumor levels of IFN-γ and VEGF.
a Photographs of H&E: hematoxylin and eosin staining of tumor tissues for histopathology; TUNEL: Terminal uridine deoxynucleotidyl transferase dUTP
nick end labeling staining assay of apoptotic cells in tumor tissue; NK1.1: IHC staining of infiltrated natural killer cells; CD11b: IHC staining of recruited
antigen-presenting cells (dendritic cells and macrophage); and CD31: IHC staining of tumor CD31-positive microvessels endothelial cells. Original
magnification: × 400. b and c are quantitative ELISA assays of the intratumor expression levels of IFN-γ and VEGF, respectively, at their protein levels.
d The mean microvessel density for each treatment group was determined by counting CD31-positive vessels in 10 high-power fields. Each experiment
was performed at least three times, and data shown are from representative experiments. Values of (b), (c) and (d) represent the mean ± SE
El-Shemi et al. Journal of Experimental & Clinical Cancer Research  (2016) 35:74 Page 10 of 16
safety on AST levels than therapy with non-armed
Ad-ΔB. In addition, we examined the morphological
changes in the liver tissues of HCC-bearing mice follow-
ing systemic treatment with PBS, Ad-ΔB, or Ad-ΔB/
TRAIL + Ad-ΔB/IL-12 (1 × 1010 VP, three times every
other day) for further assessment of Ad-induced hepato-
toxicity. As shown in Additional file 1: Figure S1, the livers
harvested from oncolytic Ad-treated mice (Ad-ΔB or Ad-
ΔB/TRAIL + Ad-ΔB/IL-12) shared similar morphology as
the PBS-treated group, indicating that oncolytic Ads did
not induce observable hepatotoxicity. Together, these re-
sults indicate that combination treatment with Ad-ΔB/
TRAIL + Ad-ΔB/IL-12 did not induce observable hepato-
toxicity, suggesting it as a safe and effective platform for
the treatment of hepatocellular carcinoma.
Discussion
Hepatocellular carcinoma (HCC) is one of the most
common deadliest cancers and its annual incidence con-
tinues to rise globally [1]. Currently, there are several
limitations in—and resistance to the therapy of HCC.
Thus, there is a necessary need for development of new
and more effective therapeutic alternatives [2–4]. To
date, cancer virotherapy, particularly mediated by onco-
lytic viruses (OAds), have emerged as a novel effective
strategy in the field of cancer therapy [6, 7, 11]. More
importantly, their combination with other treatment op-
tions, in particular with cancer gene therapy, has been
shown to strength antitumor efficacy through viral amp-
lification of the therapeutic transgene inside the tumor
cells and tissues [5–10]. With this concept, among sev-
eral kinds of transgenes are being investigated, both
TRAIL; as a unique antitumor apoptosis inducing agent
[17–19], and IL-12; as a powerful antitumor immunosti-
mulatory cytokine [23–26], seemed to represent the
most promising candidates in the theme of cancer gene
therapy. However, most of the previously published re-
ports have elucidated that single therapeutic modality,
including those mediated by TRAIL or IL-12 alone,
could not pursue in the future to achieve sufficient anti-
tumor responses and thus utilization of combination of
anti-anticancer tools, such as those mediated by dual
gene-based cancer therapy, holds the great promise for
the future of cancer eradication [13, 14, 19, 23, 27, 35].
Fig. 6 Validation of intra-tumor oncolytic adenoviral replication and the expression patterns of the encoded TRAIL and IL-12 transgenes. Three
days post-treatment of HCC-bearing mice with PBS, Ad-ΔB, or Ad-ΔB/TRAIL+Ad-ΔB/IL-12 (at a dosage regimen of 1 × 1010 VP in 200 μL PBS of each
virus; repeated three times every other day), the mice were euthanized under general anesthesia and their liver tumor tissues were harvested and
investigated to validate intratumor viral replication and expression of TRAIL and IL-12 transgenes. a and b represents intra-tumor TRAIL expression at
its mRNA and protein level, respectively, and (c) and (d) represents intra-tumor IL-12 expression at its mRNA and protein level, respectively. Data are
represented as Mean ± SE. e represents the expression of Ad E1A protein (an indicator of viral production) by western blot assay
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To the best of our knowledge the anti-cancer thera-
peutic potentiality of OAd virotherapy strategy-mediated
co-delivery of TRAIL and IL-12 genes has not been suf-
ficiently investigated far. Therefore, the present study
was designed to evaluate the therapeutic effect of a com-
bined therapy with two armed OAds (Ad-ΔB/TRAIL
and Ad-ΔB/IL-12) against the human HCC at the pre-
clinical level. Interestingly, our results showed that OAd-
mediated simultaneous delivery of TRAIL and IL-12 genes
elicited profound anti-HCC tumouricidal effects both in
vitro and in vivo; and it was closely associated with
enhanced apoptosis promotion, activation of anti-tumor
immunity and inhibition of tumor angiogenesis and vascu-
lature, than those mediated by non-armed control OAd
lacking the therapeutic genes.
In the present study, the anti-HCC effect of combined
therapy with Ad-ΔB/TRAIL+Ad-ΔB/IL-12 were mea-
sured both in vitro on human Hep3B and HuH7 cell
lines; which are well differentiated human hepatocyte-
derived cellular carcinoma cell lines commonly used in
Fig. 7 In vitro and in vivo apoptotic findings. a Flow cytometric analysis of apoptosis induction in HCC cells-treated Ad-ΔB/TRAIL plus Ad-ΔB/IL-12
(Ad-ΔB/TRAIL+IL-12), in comparison with cells treated with control Ad-ΔB or PBS, by using Annexin-V and propidium iodide (PI) fluorescence staining
assay. Each scatter plot demonstrates the percentage of early apoptotic cells (Annexin-V+cells, bottom right quadrant) and late apoptotic cells (PI+cells,
upper right quadrant). b Western blot analysis showing the intra-tumor expression levels of cleaved caspase-3 (left panel) and caspase-8 (right panel)
at day 3 after treatment of HCC-bearing mice with PBS, Ad-ΔB, or Ad-ΔB/TRAIL + Ad-ΔB/IL-12 (Ad-ΔB/TRAIL+IL-12) at a dosage regimen of 1 × 1010 VP
in 200 μL PBS of each virus; repeated three times every other day
Table 1 Biochemical findings
Treatment Liver function biomarkers Kidney function biomarkers
AST (Unit/L) ALT (Unit/L) Bilirubin (mg/dl) BUN (mg/dl) Creatinine (mg/dl)
PBS 168 ± 63.3 67 ± 27.5 0.1 27.0 ± 1.7 0.21 ± 0.02
Ad-ΔB 190 ± 36.4 52 ± 17.8 0.1 29.3 ± 5.5 0.20 ± 0.01
Ad-ΔB/TRAIL + Ad-ΔB/IL-12 118 ± 12.5 52 ± 42.2 0.2 30.6. ± 2.1 0.21 ± 0.02
HCC-bearing mice were systemically treated with PBS, controlled non-armed Ad-ΔB, or combination of Ad-ΔB/TRAIL+Ad-ΔB/IL-12; at a dosage regimen of
1 × 1010 VP/intravenous injection; three times every other day. 72 h after the last dose, serum levels of hepato-renal function biomarkers of each group were assessed.
Data are represented as mean ± SE
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studying liver cancer and its potential therapies [32, 36],
and in vivo on an orthotopic model of human HCC
established by intrahepatic implantation of Hep3B into
the liver lobes of immunodeficient nude mice. Data of
our in vitro (MTT and crystal violet assays) and in vivo
(bioluminescence imaging and H&E examination)
studies disclosed that co-therapy with Ad-ΔB/TRAIL
+Ad-ΔB/IL-12 resulted in not only cytopathic and anti-
viability effects on HCC cells but also in marked eradica-
tion of the implanted tumor cells. In agreement with our
findings, He et al. [27] have previously demonstrated
that combination of recombinant TRAIL and IL-12 sig-
nificantly sensitizes HCC cells to TRAIL’s apoptotic ef-
fect, and similarly Cai et al. [14] have elucidated the
synergistic antitumor effect of TRAIL with another
immunostimulant cytokine, IL-24, in eradication of sub-
cutaneous xenograft model of hepatoma induced by
BEL7404 cells. Likewise, Chiba et al. [35] suggested that
IL-27, a member of IL-12 cytokine family, enhances the
expression of TRAIL in human melanomas and inhibits
their tumor growth partly in a TRAIL-dependent man-
ner. Next, to clarify the efficacy of the administered
OAds to replicate and to express their encoded TRAIL
and IL-12 transgenes, we measured the expression levels
of TRAIL and IL-12 proteins as well as the levels of
adenoviral E1A protein (as an indicator of viral replica-
tion) in HCC cells and tumor tissues of different treated
groups and the results indicated that co-treatment with
Ad-ΔB/TRAIL and Ad-ΔB/IL-12 exhibited simultaneous
and efficient expression of both TRAIL and IL-12 along
with viral replication. This phenomenon has also been
previously observed with other types of OAds co-
expressing two antitumor genes [13]. Taken together, our
findings can support the recently emerged hypothesis that
dual or multi-gene-mediated oncolytic virotherapy, in
which two independent therapeutic genes are simultan-
eously expressed by OAds, provide a more satisfactory
anti-cancer therapeutic potential to target the cancer on
several levels and pathways and to deal with the complex-
ity of the tumor microenvironments through a triplex an-
ticancer effect achieved by the viral oncolytic effect and
the additive anti-cancer interactions between the encoded
two transgenes [13–15].
Cancers that are detected clinically must have evaded
antitumor immune responses to grow progressively, and
therefore the prospect of effective immunotherapies for
the treatment of patients with cancer is now becoming a
clinical reality [37]. Towards this goal, and to address
the underlying mechanisms whereby the combined ther-
apy with Ad-ΔB/TRAIL and Ad-ΔB/IL-12 cooperatively
inhibit the orthotopic model of HCC, we therefore in-
vestigated their effects on anti-tumor immune response
represented by the degree of infiltrated natural killer
cells (NK1.1 cells) and antigen presenting cells (dendritic
cells, monocyte and macrophages; CD11b- cells), as well
as by the concentrations of an antitumor-specific cyto-
kine, IFN-γ, in the harvested tumor tissues at day 3 after
the last treatment of HCC-bearing mice with either PBS,
Ad-ΔB, or Ad-ΔB/TRAIL and Ad-ΔB/IL-12. Our find-
ings demonstrated that both NK1.1-and CD11b-positive
cells were abundantly infiltrated into tumor tissues of
mice treated with Ad-ΔB/TRAIL plus Ad-ΔB/IL-12
compared with therapy with Ad-ΔB or PBS, and this ef-
fect was also accompanied with a remarkable upregula-
tion in intratumoral IFN-γ production; reflecting that
dual therapy with OAds co-expressing TRAIL andIL-12
is significantly associated with generation of anti-tumour
specific immune response. In that respect, IL-12 has
emerged as a potent inducer of antitumor immunity and
was originally identified as NK cell stimulatory cytokine
[23]; and IFN-γ is the central mediator of IL-12-induced
antitumor activities [23]. Additionally, IL-12 has shown
to upregulate TRAIL expression on NK cells [28] and
enhance TRAIL-induced apoptosis in human HCC cells
isolated from HCC-bearing patients [27]. Similarly,
oncolytic virotherapy is a potent NK cell activator; and
now there is strong evidence that NK cells are able to
directly kill tumor cells not only through IFN-γ pathway
but also through ligation of TRAIL receptors and other
mechanisms [38, 39]. Blocking of TRAIL activity (.e.g.,
by neutralizing antibodies) has been found to sig-
nificantly attenuate the cytotoxicity of human NK cells
induced by IL-12; suggesting that the expression of
TRAIL is one of the major mechanisms of NK cytotox-
icity induced by IL-12 [40]. More importantly, increased
number of NK cells in the liver tumor tissues of HCC
patients is positively correlated with their survival and
good prognosis and by contrast, dysfunction or exhaus-
tion of NK cells to produce cytotoxicity and to secret
IFN-γ in the tumor sites crucially contribute to the pro-
gression and invasion of HCC disease [41]. IFN-γ in-
duces TRAIL expression in NK cells, and synergistic
interactions between IFN-γ and TRAIL to eradicate tu-
mors have also been previously reported [42]. Likewise,
the antigen presenting cells, particularly dendritic cells
(DCs), exhibit differential anti-tumorigenic functions
and play a key role in inducing and maintaining the anti-
tumor immunity [37]. Moreover, intratumoral delivery
of a TRAIL-expressing OAd has been found to increase
the production of IFN-γ and other cytokines acting as
maturation signals for DCs as a therapeutic benefit of
engaging DCs activity in cancer virotherapy [39]. IFN-γ
acts on APCs to initiate or increase IL-12 secretion in a
positive feedback loop [23], and delivery of IL-12 gene
increases DCs proliferation and their intra-tumor infil-
tration through an IFN-γ-dependent pathway [22, 43]
have also been reported. More interestingly, early reports
have demonstrated that NK cells also enhance IFN-γ
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production by monocytes [38]; and like NK cells, there
is a subset of DCs can produce IFN-γ and mediate
TRAIL-dependent lysis of tumor cells [44]. Based on our
findings and on these previous facts we can therefore
suggest that there is a circadian crosstalk between OAds
and TRAIL and IL-12 in induction of specific anti-
tumor immunity.
Angiogenesis is central to the growth and metastasis of
cancers; and VEGF is the key driver of tumor neovascular-
ization, progression, and malignant phenotype [29, 45].
Additionally, cluster of differentiation 31 (CD31) also
plays a complex role in tumor angiogenesis [46]. These
observations provide a strong reason for the importance
of VEGF and CD31 as a potential targets in modern can-
cer therapy by developing strategies that can inhibit VEGF
and/or to disrupt its signaling pathway [45, 46]. Herein,
our findings were in harmony and elucidated that Ad-ΔB/
TRAIL and Ad-ΔB/IL-12 combination treatment was as-
sociated with a clear reduction in the intratumor expres-
sion of VEGF, CD31-positive cells, and in the microvessel
density than the effects mediated by Ad-ΔB alone; sug-
gesting a co-operative interaction between the adminis-
tered OAds and their delivered TRAIL and IL-12 genes in
halting tumor-driven angiogenesis and neovascularization.
In agreement, earlier reports have demonstrated that
OAds can attenuate tumor-driven angiogenesis [47]. Simi-
larly, it has been demonstrated that TRAIL; via caspase-8-
mediated functions [48], and IL-12; via IFN-γ-dependent
and T-cells-independent pathways [49], negatively regu-
lates VEGF-induced angiogenesis and markedly decrease
blood vessel formation in the tumor tissues.
Apoptosis is an actively orchestrated programmed cell
death pathway that serves to eliminate tumor and other
harmful cells and to maintain tissue homoeostasis; thus
it represents a strategic target for novel cancer therapies
[50]. Human HCC, like other aggressive cancers, can eas-
ily escape form endogenous apoptosis and also has a no-
torious resistant to apoptosis induced by conventional
treatment modalities. Thereby, development of new strat-
egies to specifically and efficiently trigger apoptosis in
HCC cells is a paramount therapeutic demand [12, 16]. In
agreement, we herein observed that concurrent dual
therapy with Ad-ΔB/TRAIL and Ad-ΔB/IL-12 had re-
sulted in profound promotion of apoptosis in both HCC
cells (as indicated by flow cytometry analysis) and in
tumor tissues (as observed by TUNEL assay). In support
with our findings, there is now a compelling body of evi-
dence that TRAIL is a unique death ligand for induction
of fulminant apoptotic effects in various human cancer
cell types, including HCC, while showing only negligible
effects on normal cells including normal hepatocytes
[18–20, 51]. More importantly, earlier studies have re-
ported that IL-12 sensitized HCC cells to TRAIL-induced
apoptosis, and co-therapy with soluble IL-12 and TRAIL
was synergistically interacted in apoptosis promotion and
overcame TRAIL resistance in the human HCC cells
isolated from HCC-bearing human patients or nude mice
[27]. Next, to clarify the molecular mechanism whereby
Ad-ΔB/TRAIL and Ad-ΔB/IL-12 were cooperatively inter-
acted to promote apoptosis, we measured the expression
of two common apoptosis-related proteins, caspase-3
and-8 [18], in the harvested liver tumor tissues of all treat-
ment groups and our data revealed that there was a more
significant upregulation of caspase-3 and -8 in Ad-ΔB/
TRAIL plus Ad-ΔB/IL-12-treated tumor tissues, com-
pared to therapy with Ad-ΔB. In short, our results may
imply that the observed anti-HCC effect of Ad-ΔB/TRAIL
plus Ad-ΔB/IL-12 combination therapy was, partly, medi-
ated by activating caspase cascade apoptotic pathway in
HCC cells and tumour tissues. In harmony, co-therapy
with OAd-expressing TRAIL and another type of immu-
nostimulant cytokine (IL-24) has been previously reported
to be associated with potent activation in caspase pathway,
particularly caspases-3 and -8, and apoptosis promotion
in HCC [14].
Conclusions
This preclinical study suggests for the first time that
dual therapy with Ad-ΔB/TRAIL plus Ad-ΔB/IL-12
markedly suppresses human HCC by promoting anti-
tumor apoptosis and immune activity, and also inhibits
tumor angiogenesis and neovascularization. Because of
therapeutic efficacy and easy accessibility, oncolytic
adenovirus platform-co- delivering TRAIL and IL-12
genes might be a potential therapeutic strategy for treat-
ment of human HCC. However, further studies are
warranted to evaluate this therapeutic combination and
also to explore its precise anti-tumor mechanisms.
Additional file
Additional file 1: Figure S1. Histopathological assessment of liver
tissue harvested at 3 days after systemic treatment of HCC-bearing mice
with PBS, Ad-ΔB, or Ad-ΔB/TRAIL + Ad-ΔB/IL-12 (1 × 1010 VP, three times
every other day). Each experiment was performed at least three times,
and data shown are from representative experiments. (PPTX 227 kb)
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